Targeted Prevention and Management of Mucocutaneous Candidiasis During Bimekizumab Therapy in Hidradenitis Suppurativa: A Practical Clinical Perspective
{{output}}
Bimekizumab shows high efficacy in moderate-to-severe hidradenitis suppurativa, achieving deep clinical responses and improving structural lesions such as draining tunnels. However, mucocutaneous candidiasis is the most characteristic adverse event due to IL-1... ...
